Arrowstreet Capital’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$353M Sell
2,936,330
-7,007,793
-70% -$809M 0.19% 102
2025
Q4
$1.05B Sell
9,944,123
-8,764,580
-47% -$823M 0.61% 27
2025
Q3
$1.57B Sell
18,708,703
-747,393
-4% -$61.6M 0.99% 10
2025
Q2
$1.54B Buy
19,456,096
+5,094,088
+35% +$405M 1.09% 7
2025
Q1
$1.29B Buy
14,362,008
+7,888,914
+122% +$737M 1.05% 8
2024
Q4
$644M Sell
6,473,094
-486,039
-7% -$50.1M 0.52% 32
2024
Q3
$790M Buy
6,959,133
+751,934
+12% +$89.3M 0.67% 25
2024
Q2
$768M Buy
6,207,199
+1,459,491
+31% +$188M 0.68% 28
2024
Q1
$626M Sell
4,747,708
-830,589
-15% -$102M 0.58% 35
2023
Q4
$608M Sell
5,578,297
-3,913,447
-41% -$406M 0.64% 33
2023
Q3
$977M Sell
9,491,744
-2,648,429
-22% -$285M 1.18% 12
2023
Q2
$1.4B Buy
12,140,173
+1,374,519
+13% +$156M 1.7% 7
2023
Q1
$1.15B Buy
10,765,654
+1,683,252
+19% +$182M 1.48% 8
2022
Q4
$1.01B Sell
9,082,402
-779,907
-8% -$79.7M 1.41% 6
2022
Q3
$849M Buy
9,862,309
+493,351
+5% +$44M 1.25% 9
2022
Q2
$854M Sell
9,368,958
-391,753
-4% -$34.7M 1.21% 13
2022
Q1
$801M Buy
9,760,711
+1,441,584
+17% +$114M 1% 13
2021
Q4
$638M Buy
8,319,127
+1,751,969
+27% +$140M 0.78% 16
2021
Q3
$493M Buy
6,567,158
+1,172,684
+22% +$89.2M 0.62% 25
2021
Q2
$420M Sell
5,394,474
-1,380,571
-20% -$103M 0.52% 34
2021
Q1
$498M Buy
6,775,045
+2,468,569
+57% +$182M 0.67% 24
2020
Q4
$336M Sell
4,306,476
-1,431,520
-25% -$109M 0.47% 36
2020
Q3
$454M Sell
5,737,996
-3,325,478
-37% -$260M 0.72% 18
2020
Q2
$669M Sell
9,063,474
-3,144,729
-26% -$237M 1.23% 9
2020
Q1
$896M Buy
12,208,203
+1,509,267
+14% +$119M 2.52% 5
2019
Q4
$929M Buy
10,698,936
+1,959,272
+22% +$161M 2.16% 4
2019
Q3
$702M Sell
8,739,664
-941,976
-10% -$75.5M 1.64% 6
2019
Q2
$775M Buy
9,681,640
+1,705,671
+21% +$131M 1.73% 3
2019
Q1
$633M Buy
7,975,969
+1,584,254
+25% +$118M 1.5% 6
2018
Q4
$466M Buy
6,391,715
+2,645,337
+71% +$187M 1.22% 11
2018
Q3
$254M Buy
3,746,378
+164,620
+5% +$10.5M 0.57% 42
2018
Q2
$207M Buy
3,581,758
+857,508
+31% +$48.4M 0.51% 53
2018
Q1
$142M Sell
2,724,250
-5,234,827
-66% -$283M 0.32% 78
2017
Q4
$427M Buy
7,959,077
+1,181,134
+17% +$65.5M 1.03% 17
2017
Q3
$414M Buy
6,777,943
+194,559
+3% +$11.8M 1.11% 18
2017
Q2
$403M Buy
6,583,384
+2,744,120
+71% +$167M 1.22% 14
2017
Q1
$233M Buy
+3,839,264
New +$233M 0.85% 20
2016
Q3
Sell
-51,981
Closed -$2.86M 1571
2016
Q2
$2.86M Buy
+51,981
New +$2.77M 0.01% 738
2015
Q3
Sell
-40,872
Closed -$2.22M 1439
2015
Q2
$2.22M Buy
+40,872
New +$2.29M 0.01% 610
2015
Q1
Sell
-723,943
Closed -$39.2M 1143
2014
Q4
$39.2M Sell
723,943
-4,025,117
-85% -$224M 0.22% 104
2014
Q3
$269M Sell
4,749,060
-810,121
-15% -$45.5M 1.44% 8
2014
Q2
$307M Buy
+5,559,181
New +$303M 1.58% 8

Other funds holding MRK

Arrowstreet Capital's MRK Position: Q1 2026 in Review

Arrowstreet Capital reduced its Merck (MRK) stake by 70% in Q1 2026, selling an estimated $809M and leaving 2,936,330 shares worth $353M. The position accounts for 0.19% of the portfolio, ranked #102.

Arrowstreet Capital first reported a position in MRK in Q2 2014 and has held it in 42 quarters since. The position peaked at $1.57B in Q3 2025. 3,777 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

  • Arrowstreet Capital held 2,936,330 shares of Merck worth $353M as of Q1 2026.
  • Arrowstreet Capital sold 7,007,793 Merck shares in Q1 2026, an estimated $809M.
  • Merck made up 0.19% of Arrowstreet Capital's portfolio in Q1 2026, its #102 holding.
  • Arrowstreet Capital first reported a position in Merck in Q2 2014 and has held it in 42 quarters since.
  • Arrowstreet Capital's Merck position peaked at $1.57B in Q3 2025.
  • 3,777 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on Arrowstreet Capital's 13F filing for Q1 2026, filed 14 May 2026.